MedTrace Logo

MAAM Study: Avastin and Macugen Versus Avastin Versus Macugen

NCT00531336 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2009-07-02

No results posted yet for this study

Summary

The first results of Anti-Vascular Endothelial Growth Factor (VEGF) therapy were very promising and superior to established therapies. Three different substances (all of them applied intravitreally) are available, but comparative studies have not yet been conducted. In this pilot study, the safety (number of adverse events) and efficacy (distance acuity testing retinal thickness measurement) of Avastin and Macugen applied as monotherapy will be compared to a combined treatment of Avastin followed by Macugen used for retreatment.

At least equal results of the combined therapy are expected.

Conditions

  • Macular Degeneration

Interventions

DRUG

intravitreal injection of Bevacizumab (Avastin)

1.25 mg Avastin intravitreally applied once in arm 1 every 6 weeks in arm 2

DRUG

Pegaptanib (Macugen)

0.3 mg intravitreally applied every 6 weeks as long as required

Sponsors & Collaborators

  • The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery

    lead OTHER

Principal Investigators

  • Ilse Krebs, MD · Ludwig Boltzmann Institute for Biomicroscopic Lasersurgery

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-07-31
Primary Completion
2008-12-31
Completion
2008-12-31

Countries

  • Austria

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00531336 on ClinicalTrials.gov